Gloved hands of a biologics CMO scientist removing a vial from the automatic crimper

Resources

Our biologics resources have been developed by our expert team to support your GMP sterile fill-finish journey. Here you will find our latest news, guides, technical notes and other download material for your information.

Headshot of David Collins, member of the Symbiosis Leadership team with Symbiosis background

10th January 2023

Symbiosis appoints David Collins as Commercial Director

Scottish pharma CMO has appointed David Collins as commercial director as part of its continued expansion programme. Collins will lead ...

Symbiosis Announces £1 Million Investment in an Analytical Testing Capability

4th July 2022

Symbiosis Announces £1 Million Investment in an Analytical Testing Capability

July 2022: Symbiosis Pharmaceutical Services (Symbiosis), an international contract manufacturing organisation (CMO) with headquarters in the UK, who specialise in providing ...

Symbiosis Launches a New Video Showcasing our World-class GMP Manufacturing Facility

1st June 2022

Symbiosis Launches a New Video Showcasing our World-class GMP Manufacturing Facility

We are pleased to announce the launch of our new video of the GMP manufacturing facility here at Symbiosis in ...

Symbiosis Announces Successful Completion of UK Research and Innovation (UKRI) Project

30th March 2022

Symbiosis Announces Successful Completion of UK Research and Innovation (UKRI) Project

Stirling, UK – Mar 2022: Symbiosis Pharmaceutical Services Ltd (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile global manufacture of ...

Gloved hands of a biologics CMO scientist removing a vial from the automatic crimper

11th January 2022

Symbiosis Announces Expansion of Capabilities with BSL-2 Manufacturing Upgrade

Stirling, UK – Jan, 2022: Symbiosis Pharmaceutical Services (Symbiosis), a fast-growing contract manufacturing organisation (CMO) specialising in sterile manufacture of vaccines, pharmaceuticals ...

Symbiosis Starts Producing Sevuparin for Modus Therapeutics' Future Clinical Development in Sepsis/Septic Shock

12th October 2021

Symbiosis Starts Producing Sevuparin for Modus Therapeutics' Future Clinical Development in Sepsis/Septic Shock

We’re very proud to announce that Symbiosis is working with Modus Therapeutics Holding AB, a company developing innovative treatments ...

Load more